Comparative Pharmacology
Head-to-head clinical analysis: HEPZATO versus TEMOZOLOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPZATO versus TEMOZOLOMIDE.
HEPZATO vs TEMOZOLOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Temozolomide is an alkylating agent that causes DNA methylation at O6 and N7 positions of guanine, leading to DNA damage and apoptosis. It is converted to the active metabolite MTIC under physiological conditions.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
150 mg/m2 orally once daily for 5 consecutive days of a 28-day cycle; for first cycle, then increase to 200 mg/m2/day if tolerated.
None Documented
None Documented
Clinical Note
moderateTemozolomide + Digoxin
"Temozolomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemozolomide + Digitoxin
"Temozolomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemozolomide + Deslanoside
"Temozolomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTemozolomide + Acetyldigitoxin
"Temozolomide may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
1.8 hours (range 1.3–2.5 hours) for temozolomide; the active monomethyl triazeno imidazole carboxamide (MTIC) metabolite has a half-life of approximately 2.0 hours.
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Approximately 38% of total radioactivity is excreted in urine over 7 days (5.6% as unchanged temozolomide, 12% as AIC metabolite, 21% as other polar metabolites), and less than 1% is excreted in feces.
Category C
Category D/X
Alkylating Agent
Alkylating Agent